Clinical trials: Libido Disorder
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Flibanserin Versus Placebo in Premenopausal Women With HSDD
To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women.
- Trial name
- NCT00491829
- Testing
- 50 mg qhs, 100 mg
- Where
- 86 sites in Austria, Belgium and 11 more
- Volunteers
- 945 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02333071)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 723 people
- Sponsor
- Palatin Technologies, Inc
Breast Carcinoma, Cervical Carcinoma
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal
- Trial name
- NCT03180294
- Testing
- Bupropion 150 mg XL
- Where
- 362 sites in United States
- Volunteers
- 230 people
- Sponsor
- NRG Oncology
Sexual Dysfunction, Physiological
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients.
- Trial name
- E-String (NCT00698035)
- Testing
- Testosterone Cream, Estring
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Female Sexual Dysfunction, Polycystic Ovary Syndrome
Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
SUMMARY: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive age women with a prevalence as high as 15%.
- Trial name
- Vit-D/PCOS (NCT02865187)
- Testing
- Vitamin D, Hormonal contraception
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Wright State University
Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder
Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men
The purpose of this study is to assess the tolerability, safety, and efficacy of bupropion hydrochloride sustained-release in the treatment of sexual dysfunction in men on methadone maintenance therapy.
- Conditions
- Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder, Erectile Dysfunctions
- Trial name
- NCT02593396
- Testing
- Bupropion hydrochloride sustained-release
- Where
- Malaysia
- Volunteers
- 80 people
- Sponsor
- University of Malaya
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
- Trial name
- NCT00467259
- Testing
- Testosterone Transdermal System
- Where
- 115 sites in United States
- Volunteers
- 1,271 people
- Sponsor
- Warner Chilcott
Sexual Dysfunctions, Psychological
A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder
To generate additional long-term safety and efficacy data on flibanserin in premenopausal women and establish long-term safety and tolerability of flibanserin in naturally postmenopausal women with Hypoactive Sexual Desire…
- Trial name
- NCT01103362
- Testing
- flibanserin
- Where
- 95 sites in United States, Canada
- Volunteers
- 596 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunction, Physiological, Body Image
Women's Interventions for Sexual Health: WISH
The overall objective of this program of research is to improve sexual health outcomes for women diagnosed with breast cancer. Our team is developing a multi-component intervention for the four key predictors of sexual health in…
- Conditions
- Sexual Dysfunction, Physiological, Body Image, Libido; Loss, Aversion
- Trial name
- WISH (NCT05692960)
- Testing
- Hypnotic Relaxation Intervention (HRI), Vulvovaginal Atrophy (VVA)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Tennessee, Knoxville
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT01057901
- Testing
- Flibanserin
- Where
- 100 sites in United States, Canada
- Volunteers
- 748 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder, Sexual Dysfunction
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
The overall aim of this research is to adapt and pilot test a multi-component, mindfulness-based behavioral intervention for women age 50 and older with low sexual desire.
- Conditions
- Hypoactive Sexual Desire Disorder, Sexual Dysfunction, Female Sexual Dysfunction
- Trial name
- NCT03232801
- Testing
- mindfulness-based multicomponent intervention, general health education group
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Pittsburgh
Sexual Dysfunctions, Psychological
Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria.
- Trial name
- NCT00360555
- Testing
- flibanserin, flibanserin 50mg, flibanserin 100mg
- Where
- 77 sites in United States, Canada
- Volunteers
- 1,584 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Erectile Dysfunction
A Bioavailability Study of LY2452473 and Tadalafil
This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally.
- Trial name
- NCT01401543
- Testing
- LY2452473, Tadalafil, LY900010
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Sexual Dysfunctions, Psychological
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
- Trial name
- NCT00441558
- Testing
- Flibanserin
- Where
- 196 sites in United States, Canada
- Volunteers
- 1,723 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological, Depression
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and…
- Trial name
- NCT01040208
- Testing
- flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs
- Where
- 42 sites in United States
- Volunteers
- 111 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
A randomised, double-blind, placebo-controlled, two-way crossover physiological study. Designed to evaluate the effects of melanocortin-4 receptor (MC4R) activation on brain activity patterns and behavioural psychometric measures…
- Trial name
- NCT04179734
- Testing
- Bremelanotide
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Imperial College Healthcare NHS Trust
Hypoactive Sexual Desire Disorder
Testosterone Patch's Effects on the Cardiovascular System and Libido
The purpose of this study is to examine the effect of the testosterone patch, in addition to hormone replacement therapy (HRT), on blood vessel walls, insulin levels and sexual desire.
- Trial name
- NCT01208038
- Testing
- Intrinsa Transdermal testosterone patch
- Where
- 3 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Imperial College Healthcare NHS Trust